期刊
NEUROTHERAPEUTICS
卷 18, 期 1, 页码 217-227出版社
SPRINGER
DOI: 10.1007/s13311-021-01013-w
关键词
Cannabinoids; Sleep; Hypnogram; Sleep apnea; Sleep disordered breathing; Insomnia; Marijuana; Cannabis; Restless leg syndrome; Nightmares; Narcolepsy; Parasomnia
The legalization of medicinal cannabis and cannabinoid-containing products has sparked interest in their potential therapeutic role for sleep disorders. However, current research is largely based on small sample sizes and there is a need for larger multi-center studies to assess the dose, efficacy, and safety of cannabinoids for sleep disorders.
The recent trend for legalization of medicinal cannabis and cannabinoid-containing products, together with their soporific effects, has led to a surge of interest of their potential therapeutic role in the management of some common sleep disorders, such as insomnia, sleep disordered breathing, and restless legs syndrome, and less common disorders such as narcolepsy and parasomnias. Although much of the pre-clinical and clinical data were derived from studies with relatively small sample sizes and limited by biases in assessment, and in clinical trials lack of allocation concealment, as a whole, the results indicate a potential therapeutic role for cannabinoids in the management of some sleep disorders. Clinical trials are underway for insomnia and obstructive sleep apnea management, but there remains a substantial need for rigorous large multi-center studies to assess the dose, efficacy, and safety of the various types of cannabinoids on sleep disorders. This review aims to summarize the modulatory effects of cannabinoids on sleep physiology and provide a critical evaluation of the research on their potential therapeutic benefit in various sleep disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据